medigraphic.com

2005, Number 1

<< Back Next >>

Arch Cardiol Mex 2005; 75 (1)

Analysis of the ulsefulnes of contrast echocardiography and nuclear medicine in cardiovascular affection due to autoimmune diseases

Espinola ZN, Alexánderson E, Soto ME, Flores M, Amigo M

Language: Spanish
References: 42
Page: 42-48
PDF size: 104.77 Kb.


ABSTRACT

A significant correlation between autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and premature or accelerated coronary atherosclerosis was found. The objectives of the study were: a) evaluate myocardial perfusion in patients with rheumatic diseases by means of contrast echocardiography (CE) and to establish its usefulness as compared to the results obtained by nuclear medicine (NM) (reference method). b) evaluate the prevalence of alterations in subclinical myocardial perfusion in autoimmune diseases and to establish a strategy to evaluate the cardiovascular changes in this disease. Myocardial perfusion in 37 outpatients of the rheumatology department was evaluated by CE at rest and with pharmacological stress (dobutamine) and NM. The prevalence of alterations in the myocardial perfusion in autoimmune diseases by CE and NM, when these methods were analyzed independently or when both methods were used was 27%. The positive predictive value (PPV) and negative predictive value (NPV) of both tests was 80% and 93%, respectively, the sensitivity was 80% and the specificity was 93%. The prevalence of alterations of perfusion in the primary antiphospholipid syndrome (PAPS) was of 30%. In this patients it was found that when both diagnostic tests are performed, NM reaches a sensitivity of 100% if the CE is positive and an specificity of 100% when the CE is negative. We can conclude that it is important to determine the presence of subclinic coronary artery disease in patients with autoimmune disease by noninvasive studies such as Sestamibi SPECT and/or CE for assessment of myocardial perfusion in order to plan an adequate treatment and follow-up.


REFERENCES

  1. Ghaffari Sasan MD: Detection and Management of coronary artery disease in patients with rheumatologic disorders. In Rheumatic diseases Clinics of North America. 1999; 25(3): 657-668.

  2. French WJ: Trends in Acute Myocardial Infarction Management: Use of the national registry of myocardial infarction in quality improvement. Am J Cardiol 2000; 85: 5B-9B.

  3. Rabbani R, Topol E: Strategies to achieve coronary arterial plaque stabilization. Cardiovasc research 1999; 41: 402-417.

  4. Hamm Cristhian, Braunwald Eugene: A classification of Unstable angina revisited. Circulation 2000;102: 118-122.

  5. Lusis AJ: Atherosclerosis. Nature 2000; 407: 233-241.

  6. Ross R: Atherosclerosis – An inflammatory disease. NEJM 1999; 340(2): 115-125.

  7. George J, Afek A, Gilburd B, Harats D, Shoenfeld Y: Autoimmunity in atherosclerosis: lessons from experimental models. Lupus 2000; 9: 223-227.

  8. De Winther M, Hofker M: Scavenging new insights into atherogenesis. J Clin Invest 2000; 105(8): 1039-1041.

  9. Wierzbicki AS: Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. Lupus 2000; 9: 194-201.

  10. Gladman DD, Urowitz MB: Morbidity in systemic lupus erythematosus. J Rheumatol 1987; 14(S13): 223-226.

  11. Petri M, Pérez-Gutthann S, Spence D, Hochberg MC: Risk factor for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-519.

  12. Sultan H, Berson J, Mirotznik J, Ginzler EM: Lack of evidence for corticosteroids as a risk factor for coronary artery disease in systemic lupus erythematosus. Northeast Region American College of Rheumatology Meeting, New York, June 1994.

  13. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TAQ, Jansen-McWilliams L, D’Agostino RB, Kuller LH: Age-specific incidence rates of myocardial infarction and angina in women with Systemic Lupus Erythematosus: Comparison with the Framingham study. Am J Epidemiol 1997: 145: 408-415.

  14. Badui E, García-rubi D, Robles E, Jiménez J, Juan L, Deleze M, Díaz A, Mintz G: Cardiovascular manifestations in systemic lupus erythematosus; prospective study of 100 patients. Angiology 1985; 36: 431-441.

  15. Hosenpud JD, Montanaro A, Hart MV, Haines JE, Specht HD, Bennett RM, Kloster FE: Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984; 77: 286-292.

  16. Ginzler E, Stein R, Solomon N, Frank F: Coronary artery disease and ventricular function in long-term systemic lupus erythematosus patients. American Rheumatism Association Meeting, Atlanta, May 1980.

  17. Bruce IN, Burns RJ, Gladman DD, Urowitz MB: High prevalence of myocardial perfusion abnormalities in women with LES. Arthritis Rheum 1997; 40: S219.

  18. Bruce IN, Burns RJ, Gladman DD, Urowitz MB: Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with SLE. I. Prevalence and distribution of abnormalities. J Rheumatol 2000; 27: 2372-2377.

  19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR: The American Rheumatism Association 1987 Criteria. Arthritis Rheum 1988;31:315-328.

  20. 20.Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winhester RJ: The 1982 revised criteria for the classification of systematic lupus erythematosus (SLE). Arthritis Rheum 1982; 25: 1271-1277.

  21. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JO, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta M: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42(7): 1309-1311.

  22. Rainbird A, Mulvagh S, Oh K, McCully R, Klarich K. Contrast dobutamine stress echocardiography: Clinical practice assessment in 300 consecutive patients. J Am Soc Echocardiogr 2001; 14: 378-85.

  23. Main M, Grayburn P: Clinical applications of transpulmonary contrast echocardiography. Am Heart J 1999; 137(1): 144-153.

  24. Porter TR, Xie F, Li S, D’Sa A, Rafter P: Increased ultrasound contrast and decreased microbubble destruction rates with triggered ultrasound imaging. J Am Soc Echocardiogr 1996; 9: 599-605.

  25. Porter TR, Xie F, Kricsfeld D, Ambrusterbe RW: Improved myocardial contrast with second harmonic transient response imaging in humans using intravenous perfluorocarbon-exposed sonicated dextrose albumin. J Am Coll Cardiol 1996; 27: 1496-501.

  26. Crouse L, Kramer P: Stress echocardiography: Technical considerations. Progress cardiovasc dis 2001; 43(4): 303-314.

  27. Moder KG, Miller TD, Tazelaar HD: Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999; 74: 275-284.

  28. Ward MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338-346.

  29. Manzi S, Wasko M-C: Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000; 59: 321-325.

  30. Cisternas M, Gutierrrez MA, Klaassen J, Acosta AM, Jacobelli S: Cardiovascular risk factors in chilean patients with rheumatoid arthritis. J Rheumatol 2002; 29: 1619-1622.

  31. Mutru O, Laakso M, Isomaki H, Koota K: Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989; 76: 71-77.

  32. Cohn JN: Arterial compliance to stratify cardiovascular risk more precision in therapeutic decision making. Am J Hypertens 2001; 14: 258S-63S.

  33. Wong M, Toh L, Wilson A, Roeley K, Karschimkus C, Prior D, Romas E, Clemens L, Dragicevic G, Harianto H, Wicks I, Best J, Jenkins A: Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis and Rheum 2003; 48: 81-89.

  34. Motoyoshi K, Takaku F: Serum cholesterol-lowering activity of human monocytic colony-stimulating factor. Lancet 1989; 2: 326-327.

  35. De Viliers WJ, Farser IP, Hughes DA, Doyle AG, Gordon S: Macrophage-colony-stimulating factor selectively enhances macrophage scavenger receptor expression and function. J Exp Med 1994; 180: 705-709.

  36. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler Nj, Terkeltaub R, Pierangeli SS, Branch DW, palinski W, Witztum JL: Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98: 815-825.

  37. Libby P: The pathogenesis of atherosclerosis. In: Kasper DL, Ed. Harrison’s Principles of Internal Medicine. 16th ed. United States of America, 2005. pp. 1425-1430.

  38. Amengual O, Atsumi T, Khamashta MA, Tinahones F, Hughes GRV: Antibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol 1997; 36: 964-968.

  39. Vaarala O, Alfthan G, Jauhiainen M, Leirsalo-Repo M, Aho K, Palosuo T: Crossreaction between antibodies to oxidized lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-925.

  40. Bruce IN, Gladman DD, Ibañez D, Urowitz MB: Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. J Rheumatol 2003; 30: 288-291.

  41. Lin JJ, Hsu HB, Sun SS, Wang JJ, Ho ST, Kao CH: Single photon emission computed tomography of technetium-99m tetrofosmin myocardial perfusion imaging in patients with systemic lupus erythematosus- A preliminary report. Jpn Heart J 2003; 44: 83-89.

  42. Schillaci O, Lagana B, Danieli R, Gentile R, Tubani L, Baratta L, Scopinaro F: Technetium-99m Sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. Eur J Nucl Med 1999; 26: 713-717.




2020     |     www.medigraphic.com